Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

702

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

July 1, 2029

Study Completion Date

November 1, 2029

Conditions
Gastric Cancer
Interventions
DRUG

Huaier granule

Huaier granule, oral administration, 10g each time, 3 times a day. Continuous medication until disease progression, the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, or until the researcher determines that the participants will no longer benefit, whichever occurs first. After disease progression, whether to continue the medication or not should be determined by the researcher and participant together. Participants will start taking Huaier granule within 1 to 3 weeks after surgery.

DRUG

Oxaliplatin

Participants will receive intravenous infusion of 130 mg/m² oxaliplatin on the first day of treatment cycle.

DRUG

Tegafur, Gimeracil and Oteracil Potassium

Participants will receive oral Tegafur, Gimeracil and Oteracil Potassium (40 mg/m², twice a day) for 2 weeks, followed by 1 week of rest.

Trial Locations (2)

430022

Wuhan Union Hospital, Wuhan

Unknown

The Affiliated Hospital of Qingdao University, Qingdao

All Listed Sponsors
collaborator

LinkDoc Technology (Beijing) Co. Ltd.

INDUSTRY

lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

NCT05498766 - Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients | Biotech Hunter | Biotech Hunter